Nephrogenic Fibrosing Dermopathy/Nephrogenic Systemic Fibrosis

Nephrogenic Fibrosing Dermopathy/Nephrogenic Systemic Fibrosis

Identification: nnj_mj07A2
Issue: May-June 2007
Volume: Vol. 34, No. 3

Standard: $30.00

Description

This article is available to members for free.

Goal: Recognize nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis (NFD/NSF) in patients with chronic kidney disease (CKD).

Objectives:

  1. Identify the clinical manifestations of a patient presenting with NSF.
  2. Discuss the FDA advisory concerning contrast enhanced MRI with gadodiamide in patients with CKD.
  3. List the treatment options for NSP that are under investigation.


Note: The authors reported no actual or potential conflict of interest in relation to this continuing education article.

Author(s)

Credits

Credits: None available.

You must be logged in and own this product in order to post comments.

Print Certificate
Review Answers
Print Transcript
Completed on: token-completed_on
Review Answers
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content
token-speaker-name image
token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content